Search Results
Month: January 2026
Expanded Access of Kv7.2 Channel Activators
Kv7.2 Channel Activators In many cases, KCNQ2-DEE is caused by reduced Kv7.2 potassium channel activity. Because of this, therapeutics that boost the activity of these channels are likely to be an effective treatment approach. Support for this comes from research showing that a Kv7.2 channel opener, retigabine (also called ezogabine), reduced seizures and improved alertness,…
Q2 Quick Notes #08: Electronic Medical Records Help Show Trajectories of SCN8A-Related Disorders
Excerpt Researchers used existing medical records and data from the International SCN8A Registry to create individual profiles of people with SCN8A-related disorders. When combined, they revealed common patterns in how the disorder progressed and how symptoms were treated. What It’s About Longitudinal data from 80 different people with SCN8A-related disorders were extracted from electronic records…
Q2 Quick Note #07: Carbamazepine Improves Memory in Kcnq2 Mouse Model
Researchers treated mice carrying a Kcnq2 gene variant with a sodium channel-blocking drug called carbamazepine. Mice that received the drug had fewer seizures and performed better on memory-related tests compared to mice given a placebo. What It’s About Scientists studied mice that were genetically modified to carry the same KCNQ2 gene variant found in a…
Praxis EMERALD Clinical Trial
KCNQ2 Cure hosted a webinar for the KCNQ2 community featuring a discussion with Praxis Precision Medicines. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for disorders of the central nervous system characterized by an imbalance between neuronal excitation and inhibition, a mechanism that is highly relevant to many developmental and epileptic…